Molecular Hydrogen Inhibits MAPK Phosphorylation to Treat Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively modulate mitogen-activated protein kinase (MAPK) levels to control inflammation, as the precise mechanism of hydrogen in suppressing inflammatory responses remains unclear, and existing treatments for endotoxin shock and inflammation have limitations.
Innovation Solution
Administering a composition containing hydrogen to down-regulate TNF-α, IL-6, and MAPK phosphorylation, specifically targeting extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK) in monocyte lineage cells, while up-regulating MKP-1 to suppress inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional anti-inflammatory treatments are used to suppress inflammatory responses, then inflammation is reduced, but side effects and limitations occur
Solution Approach 1:
The patent extracts and isolates molecular hydrogen (H2) as the specific active component responsible for anti-inflammatory effects. By focusing on H2 alone rather than complex conventional anti-inflammatory drugs, the treatment achieves inflammation suppression without the harmful side effects associated with traditional medications.
Solution Approach 2:
The patent changes the fundamental parameter of treatment from chemical drug administration to molecular hydrogen delivery. This parameter change transforms the treatment mechanism from pharmacological intervention to a safer, more selective approach that modulates inflammatory pathways without causing systemic side effects.
2Reliability
If the mechanism of hydrogen in suppressing inflammatory responses is not understood, then precise control of inflammation is limited, but research progress is hindered
Solution Approach 1:
The patent incorporates feedback mechanisms by measuring inflammatory markers (such as TNF-α, IL-6, and MAPK phosphorylation levels) to assess the effectiveness of hydrogen treatment. This feedback enables precise control and optimization of hydrogen therapy dosing and timing to achieve desired anti-inflammatory outcomes.
Solution Approach 2:
The patent performs preliminary actions by administering hydrogen before inflammatory responses fully develop or before therapeutic intervention is needed. This preventive approach allows for better control of inflammatory processes and reduces the need for more aggressive treatments later.
3Reliability
If existing treatments for endotoxin shock are used, then some protective effect is achieved, but effectiveness is limited and side effects occur
Solution Approach 1:
The patent converts the harmful effects of endotoxin-induced inflammation into a beneficial therapeutic opportunity by using molecular hydrogen to selectively target and neutralize the harmful inflammatory pathways. Hydrogen transforms the toxic inflammatory response into a controlled, reversible process without damaging side effects.
Solution Approach 2:
Molecular hydrogen acts as an intermediary substance that mediates between the harmful endotoxin stimulus and the body's inflammatory response. Rather than directly blocking endotoxin or aggressively suppressing immunity, hydrogen provides a gentle buffering effect that modulates the inflammatory cascade, allowing the body to naturally resolve the shock while preventing excessive damage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of hydrogen effectively reduces inflammation by down-regulating pro-inflammatory cytokines and MAPK phosphorylation, providing a novel, side-effect-free approach to treating endotoxin shock and inflammation, and offering a diagnostic method for diseases related to the MAPK pathway.
Implementation Method 1
the ability of H2 to reduce the reactive oxygen species (ROS) generated in the course of brain injury was revealed to be responsible for this H2-mediated therapeutic effect
Implementation Method 2
suppressing mitogen-activated protein kinase (MAPK) phosphorylation, and down-regulating inflammatory responses
Data Source
AI summary
A method of treating inflammation in a subject by administering a composition including hydrogen, releasing hydrogen in the subject, suppressing mitogen-activated protein kinase (MAPK) phosphorylation and upregulating expression of MKP-1, and down-regulating inflammatory responses of monocyte lineage cells.